David K. Dean - Concepedia

Author

David K. Dean

GlaxoSmithKline (United Kingdom)

Also Known As

D. K. DEAN, D.K. Dean, DAVID DEAN, DAVID K. DEAN, David Dean, David K Dean, David K. Dean, David. Dean, Dean, D.K.

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Molecular Discovery (United Kingdom)Centre for Cancer Biology Cypralis (United Kingdom)Gilead Sciences (United States)

About

David K. Dean is an author at GlaxoSmithKline (United Kingdom) specializing in pharmacology, biochemistry, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Biochemistry	14	16	594
2	Medicine	12	13	557
3	Natural Sciences	10	10	396
4	Engineering	4	4	251
5	Health Sciences	1	1	59

David K. Dean

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
The identification of potent and selective imidazole-based inhibitors of B-Raf kinase Andrew K. Takle, Murray J. B. Brown, Susannah Davies, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetBiochemistryB-raf KinaseNatural Sciences	2005	189
Rate Acceleration of the Baylis−Hillman Reaction in Polar Solvents (Water and Formamide). Dominant Role of Hydrogen Bonding, Not Hydrophobic Effects, Is Implicated Varinder K. Aggarwal, David K. Dean, Andrea Mereu, The Journal of Organic Chemistry EngineeringBaylis-hillman ReactionOrganic ChemistryChemistryRate Acceleration	2001	184
Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle Richard L. Mackman, Victoria A. Steadman, David K. Dean, Journal of Medicinal Chemistry	2018	75
Discovery and structure–activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor Muna Abdi, Paul Beswick, Andy Billinton, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryMedicineP2x7 ReceptorMechanism Of Action	2010	70
Mechanism of action of species‐selective P2X<sub>7</sub>receptor antagonists Anton D. Michel, Sin‐Wei Ng, Shilina Roman, British Journal of Pharmacology	2009	64
The contribution of classical (beta1/2-) and atypical beta-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel beta3-adrenoceptor agonists of differing selectivities. Matthew V. Sennitt, Alberto J. Kaumann, Peter Molenaar, PubMed PharmacotherapyMetabolic SyndromeAdrenal GlandHealth SciencesHuman White Adipocytes	1998	59
Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A Victoria A. Steadman, S. Pettit, Karine G. Poullennec, Journal of Medicinal Chemistry	2017	57
Non thiazolidinedione antihyperglycaemic agents. 1: α-Heteroatom substituted β-phenylpropanoic acids Derek R. Buckle, Barrie C. C. Cantello, Michael A. Cawthorne, Bioorganic & Medicinal Chemistry Letters β-Phenylpropanoic AcidsMedicinal ChemistryBiochemistryNatural SciencesPharmacological Agent	1996	46
(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors Mark J. Bamford, Michael J. Alberti, Nicholas Bailey, Bioorganic & Medicinal Chemistry Letters -1,2,5-Oxadiazol-3-ylamine DerivativesMedicinal ChemistryMedicineMechanism Of ActionPharmacological Agent	2005	43
Involvement of azomethine ylides in the thermal rearrangement of aziridinyl ketones to pyrroles Albert Padwa, David K. Dean, Toyonari Oine Journal of the American Chemical Society Aziridinyl KetonesEngineeringChemical AnalysisAzomethine YlidesAltmetric Attention Score	1975	36

Page 1